As of December 15, 2025, Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392.SS) reports a Gross Margin of 61.72%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Gross Margin
Over recent years, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Gross Margin has shown a moderate pattern. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 61.72% |
| 2023-12-31 | 81.99% |
| 2022-12-31 | 89.35% |
| 2021-12-31 | 85.26% |
| 2020-12-31 | 79.98% |
This slight upward trend highlights how Beijing Wantai Biological Pharmacy Enterprise Co Ltd manages its operational efficiency and pricing power over time.
Comparing Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Gross Margin to Peers
To better understand Beijing Wantai Biological Pharmacy Enterprise Co Ltd's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392.SS) | 61.72% |
| Imeik Technology Development Co Ltd (300896.SZ) | 94.64% |
| Chengdu Kanghua Biological Products Co Ltd (300841.SZ) | 94.08% |
| InnoCare Pharma Ltd (9969.HK) | 93.70% |
| Xiamen Amoytop Biotech Co Ltd (688278.SS) | 93.49% |
| Beijing Balance Medical Technology Co Ltd (688198.SS) | 88.34% |
Compared to its competitors, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.